Research progress in the application of drug eluting beads transarterial chemoembolization as bridge therapy for hepatocellular carcinoma before liver transplantation
10.3760/cma.j.cn121382-20200105-00315
- VernacularTitle:载药微球化疗栓塞治疗在肝癌肝移植术前应用的现状与进展
- Author:
Hao WANG
1
;
Haijun GAO
;
Zhengjia YI
;
Guang CHEN
Author Information
1. 天津市第一中心医院放射科 300192
- From:
International Journal of Biomedical Engineering
2020;43(3):255-259
- CountryChina
- Language:Chinese
-
Abstract:
The aims of bridging treatments before liver transplantation is to prevent the tumor from progressing to exceed the liver transplantation standards during the waiting period of patients with hepatocellular carcinoma (HCC), and to downgrade the HCC to meet the liver transplantation standards so as to reduce the postoperative tumor recurrence rate. Conventional transcatheter arterial chemoembolization (cTACE) has the disadvantages of large systemic adverse reactions and great influence on liver function. Drug-eluting beads (DEBs) are a new type of embolization material. Compared with cTACE, DEB-TACE can continuously and stably release chemotherapeutic drugs locally on the tumor for several weeks. Moreover, the concentration of the chemotherapeutic drug in the blood circulation is extremely low, which can effectively avoid systemic reactions caused by chemotherapy drugs, and is more effective in thebridging treatments of liver transplantation. In this paper, the current status and research progress of DEB-TACE treatment before liver transplantation for liver cancer were reviewed.
